Stephanie A Vuijk, Maria M E Jongsma, Britt M Hoeven, Maarten A Cozijnsen, Merel van Pieterson, Tim G J de Meij, Obbe F Norbruis, Michael Groeneweg, Victorien M Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick F van Rheenen, Michiel P van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J Poley, Johanna C Escher, Lissy de Ridder
BACKGROUND: Data on cost-effectiveness of first-line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed. AIM: To investigate the cost-effectiveness of first-line infliximab compared to conventional treatment in children with moderate-to-severe Crohn's disease. METHODS: We included patients from the Top-down Infliximab Study in Kids with Crohn's disease randomised controlled trial...
April 21, 2024: Alimentary Pharmacology & Therapeutics